MONTREAL, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. ("Knight") (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today it has received expedited regulatory approval under ANVISA’s rare disease pathway for NIKTIMVO® (axatilimab), for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients 6 years and older weighing at least 40 kg.1
MONTRÉAL, 06 oct. 2026 (GLOBE NEWSWIRE) -- Thérapeutique Knight inc. (TSX : GUD) (« Knight »), société pharmaceutique panaméricaine (hors États-Unis), a annoncé aujourd’hui avoir reçu une autorisation réglementaire accélérée, dans le cadre de la voie réglementaire de ANVISA pour les maladies rares, pour NIKTIMVO® (l’axatilimab), destiné au traitement de la maladie chronique du greffon contre l’hôte (cGVHD) après l’échec d’au moins deux lignes antérieures de traitement systémique chez les patients adultes et pédiatriques âgés de 6 ans et plus pesant au moins 40 kg.1
MONTRÉAL, 06 oct. 2026 (GLOBE NEWSWIRE) -- Thérapeutique Knight inc. (TSX : GUD) (« Knight »), société pharmaceutique panaméricaine (hors États-Unis), a annoncé aujourd’hui le lancement de TAVALISSE® (fostamatinib disodique hexahydraté) au Brésil, pour le traitement des patients adultes atteints de thrombocytopénie immunitaire chronique (TPI) présentant une réponse insuffisante à un traitement antérieur.1
MONTREAL, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. ("Knight") (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today the launch of TAVALISSE® (fostamatinib disodium hexahydrate) in Brazil, for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.1
MONTRÉAL, 29 sept. 2026 (GLOBE NEWSWIRE) -- Thérapeutique Knight inc. (« Knight ») (TSX : GUD), société pharmaceutique panaméricaine (hors États-Unis), a annoncé aujourd'hui la signature d'une entente de distribution exclusive avec Kyowa Kirin International (« KKI »), filiale en propriété exclusive de Kyowa Kirin Co., Ltd. (TSE : 4151) (« Kyowa Kirin »), société pharmaceutique internationale spécialisée basée au Japon, pour le mogamulizumab (commercialisé sous le nom de POTELIGEO® aux États-Unis et en Europe) dans certains pays d'Amérique latine. En vertu des modalités de cette entente, Knight sera responsable d'obtenir l'approbation réglementaire et de commercialiser le mogamulizumab au Brésil, au Mexique, en Colombie et en Argentine.
You are now leaving the Knight Canada website and entering other country website where the information presented may have different labeling than in Canada, and the Canadian Privacy Policy does not apply. You are solely responsible for your interactions with that website.
Click here to continue
You are now leaving the Knight Canada website and entering other country website where the information presented may have different labeling than in Canada, and the Canadian Privacy Policy does not apply. You are solely responsible for your interactions with that website.
Click here to continue
You are now leaving the Knight Canada website and entering other country website where the information presented may have different labeling than in Canada, and the Canadian Privacy Policy does not apply. You are solely responsible for your interactions with that website.
Click here to continue
You are now leaving the Knight Canada website and entering other country website where the information presented may have different labeling than in Canada, and the Canadian Privacy Policy does not apply. You are solely responsible for your interactions with that website.
Click here to continue
You are now leaving the Knight Canada website and entering other country website where the information presented may have different labeling than in Canada, and the Canadian Privacy Policy does not apply. You are solely responsible for your interactions with that website.
Click here to continue
You are now leaving the Knight Canada website and entering other country website where the information presented may have different labeling than in Canada, and the Canadian Privacy Policy does not apply. You are solely responsible for your interactions with that website.
Click here to continue
You are now leaving the Knight Canada website and entering other country website where the information presented may have different labeling than in Canada, and the Canadian Privacy Policy does not apply. You are solely responsible for your interactions with that website.
Click here to continue
You are now leaving the Knight Canada website and entering other country website where the information presented may have different labeling than in Canada, and the Canadian Privacy Policy does not apply. You are solely responsible for your interactions with that website.
Click here to continue
You are now leaving the Knight Canada website and entering other country website where the information presented may have different labeling than in Canada, and the Canadian Privacy Policy does not apply. You are solely responsible for your interactions with that website.
Click here to continue
You are now leaving the Knight Canada website and entering other country website where the information presented may have different labeling than in Canada, and the Canadian Privacy Policy does not apply. You are solely responsible for your interactions with that website.
Click here to continue
You are now leaving the Knight Canada website and entering other country website where the information presented may have different labeling than in Canada, and the Canadian Privacy Policy does not apply. You are solely responsible for your interactions with that website.
Click here to continue